Researchers Uncover Promising Combination for Renal Cancer
Researchers Uncover Promising Combination for Renal Cancer by Angela Mohan on January 21, 2021 at 12:29 PM Loss of ACE2 mediates resistance to classical treatments to renal cell carcinoma (RCC) , and treatment with a drug that could downstream ACE2, can improve tumor responses in RCC and prolong survival. Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 p...
Source: medindia.net